|
TTP488 Clinical Trials
1 actively recruiting trial across 1 location
Also known as: Azeliragon
Washington D.C., District of Columbia1 trial
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Georgetown Lombardi Comprehensive Cancer Center
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.